LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.30 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.40M

Average 0.23M

Returns on capital

LB Pharmaceuticals Inc Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-8.4%

avg 31.6%

ROIC

-9.9%

avg -75.0%

ROA

-8.1%

avg -69.2%

Analysis

ROA is currently the strongest return metric at -8.1% versus its period average of -69.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Heather D. Turner

Chief Executive Officer & DirectorUSD 1.02M53——

Soffer

Chief Operating & Business OfficerUSD 644.8K49——

Anna Eramo

AdvisorUSD 616.93K51——

Susan G. Kozauer

Chief Medical OfficerUSD 616.93K54——

Christopher Zergebel

Senior Vice President of Clinical Operations————

Joseph Miller

Chief Financial Officer—52——

Lindsay Beaupre

Senior VP of People & Culture————

Minako Pazdera

General Counsel————

James Rawls

Senior Vice President of Regulatory Affairs————

Richard Silva

Senior Vice President of Technical Operations—58——

Ellen Rose

Senior Vice President of Corporate Affairs————

Kaya Pai Panandiker

Chief Commercial Officer—49——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$28.62

Sells

0

$0.00

Net Transaction Value

+$28.62

Net buying

Most Active

Deep Track Biotechnology Master Fund, Ltd.

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 30, 26

Deep Track Biotechnology Master Fund, Ltd.

Direct

Buy$28.6

Summary

Insiders reported 1 buys worth $28.62 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $28.62. Deep Track Biotechnology Master Fund, Ltd. was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does LB Pharmaceuticals Inc Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LBRX's management, answered from reported figures.

Who manages LBRX?

LB Pharmaceuticals Inc Common Stock (LBRX) lists 12 active executives. The top listed executive is Anna Eramo, Advisor.

Are LBRX insiders buying or selling?

Recent insider activity shows net buying of $14.89M.